Conscientious integration of the best available evidence in the care of an individual patient could be challenging for a busy clinician. A well-conducted systematic review can adequately inform not only the clinicians, but also the policy makers and researchers about the benefits and risks of a particular intervention. In this article, we describe how to critically appraise the methods and interpret the results of a systematic review of interventional trials and apply the findings of a systematic review to the clinical questions.
I N T R O D U C T I O N
Mrs DS is a 55-year-old patient with Stage G4 chronic kidney disease (CKD) due to autosomal dominant polycystic kidney disease [estimated glomerular filtration rate (eGFR) 15-29 mL/min/1.73 m 2 ]. She is seeing you in a 'low clearance' clinic for routine care. She has an eGFR of 23 mL/min/1.73 m 2 , well-controlled blood pressure (138/86 mmHg) and has no symptoms related to her CKD. She has not experienced a previous cardiovascular event and has no family history of premature cardiovascular disease in family members who are unaffected by CKD. She has never smoked and is not diabetic. Her body mass index is 24 kg/m 2 . She hopes to receive a kidney transplant from her husband when she requires kidney replacement therapy.
Mrs DS's recent fasting serum lipids are as follows: total cholesterol 5.6 mmol/L (217 mg/dL), low-density lipoprotein (LDL) cholesterol 3.5 mmol/L (135 mg/dL), very low-density lipoprotein (VLDL) cholesterol 1.0 mmol/L (39 mg/dL), highdensity lipoprotein cholesterol 1.1 mmol/L (43 mg/dL) and triglyceride 2.1 mmol/L (81 mg/dL). She is only taking an angiotensin-converting-enzyme inhibitor for blood pressure. Based on the American College of Cardiology/American Heart Association (ACC/AHA) Cardiovascular Risk Assessment Tool, the estimated 10 years and lifetime risks for atherosclerotic cardiovascular disease for Mrs DS are 4.3 and 39%, respectively. Mrs DS has searched the Internet for information about the best practice for her cardiovascular risk and would like to consider lipid-lowering treatment.
We will explore the following clinical questions:
(i) What are the clinical benefits and harms of statin therapy for lowering Mrs DS's risk of cardiovascular events?
(ii) What is the magnitude and certainty of any treatment benefit?
(iii) How confident are we of the estimated treatment benefits of lipid lowering and do they apply to this clinical situation? (iv) What should we advise her about ongoing statin therapy when she needs kidney replacement therapy?
This is a very common scenario for clinicians caring for people with CKD. Patients and their families have increasing access to information and are better informed than ever before. Data from randomized trials of statin treatment are abundant and potentially conflicting [1] [2] [3] -do the treatment effects of statin therapy differ based on the severity of CKD? In fact, over 80 randomized trials or post hoc analyses of randomized trials provide information about statin therapy in the setting of CKD. Two systematic reviews on this topic have been published side by side in the same issue of the Annals of Internal Medicine in 2012 [4, 5] . Let us see how the results of these reviews might help us recommend a treatment plan for Mrs DS. We will discuss how to interpret the methods and findings of these systematic reviews in reference to this clinical case and decide how confident we are of the treatment effects of statin treatment for Mrs DS. The key features of each systematic review are detailed in Table 1 , and their results are summarized in Table 2 . By the end of reading this article you should be able to: (i) consider whether a systematic review applies to your clinical question, (ii) critically appraise the methods of a review, (iii) read a forest plot (the summary of treatment effects from available trials), (iv) interpret how treatment effects might be different in different settings (subgroup and meta-regression analyses) and (v) apply the findings of a systematic review to clinical questions.
S T E P 1 : D O E S T H E S Y S T E M AT
When considering whether evidence is related to our clinical question, it is helpful to formulate our clinical question in a standard format known as the PICO. Traditionally, the systematic review is designed to include all the studies relating to a specific PICO (Population-Intervention-Comparison-Outcome Authors of a systematic review should state the clearly formulated question that they have used to identify, select and critically appraise relevant treatment data for inclusion in the review. In the first systematic review [4] , the purpose was 'to summarize the benefits and harms (O) of statin therapy (I) for adults with CKD (P)'. While we need to read further to find out what is meant by the outcomes of 'benefits and harms' and how CKD is defined, this systematic review appears relevant to Mrs DS (in fact, she may have found something similar in Google). Likewise, in the second review [5] , the purpose was to 'synthesize evidence examining the effect of lipidlowering therapy (I) on clinical outcomes (O) in persons with CKD (P)'. Again we need to clarify the definitions for clinical 
F U L L R E V I E W
S y s t e m a t i c r e v i e w s o f i n t e r v e n t i o n a l t r i a l s outcomes and CKD and it appears this review includes lipidlowering treatment other than statins, but we can now consider these two reviews relevant to our case management for Mrs DS.
S T E P 2 : WA S T H E S Y S T E M AT
As with clinical trials, it is recommended by guidelines for reporting systematic reviews that a protocol is made available that pre-specifies the objectives and methods of the review including the primary outcomes of interest, how the reviewers will extract information about these outcomes and the methods that will be used to quantitatively summarize the outcome data [6] . While protocols can be changed legitimately, the reader may wish to consider how a change in the pre-specified primary outcome might change the results of a systematic review. In the two example reviews we are considering, the first reported methods according to published protocols although did not specify a primary outcome [4] , while the second specified an unreferenced protocol and also did not state a primary outcome [5] . The conclusions of the review, while appearing to include the key expected outcomes (mortality and cardiovascular events), might have been different if other primary outcomes had been chosen.
S T E P 3 : WA S T H E S E A R C H FO R T H E R E L E VA N T S T U D I E S E X P L I C I T A N D CO M P R E H E N S I V E ?
A systematic review is only as good as the literature search that created it. If many of the relevant studies are not included (for whatever reason), then the overall results may not be reliable for making clinical decisions. When considering whether the systematic review is likely to have included the potentially relevant trials, we can assess both the electronic search strategy that has been used to identify citations and which databases were explored. As not all data for a research question are electronically indexed in MEDLINE or Embase and might be 'hiding' in the grey literature (for example, conference proceedings that were never published in full), searching a database that locates citations by methods such as handsearching can increase the yield and the completeness of the available citations in the review. Consider briefly which search terms you might expect to see in the search strategy and assess whether these were included in the systematic review.
In the first review, the authors searched Embase, the Cochrane Central Register of Randomised Trials (CENTRAL) and the Cochrane Renal Group's specialized register of trials but have not described the search terms they have used (making these available on request and provided in previous publications) [4] . So while the search appears to be comprehensive (four databases searched), we are not sure that all the relevant terms have been included without further effort on our part (getting the original protocol publication or writing to the authors). To note, the Cochrane Renal Group specialized register includes data from automated awareness alerts from selected renal journals, handsearching of renal journals and proceedings of major renal conferences and searches of international clinical trials' registries and may contain considerable 'grey literature' that is not available from other sources. In the second review, authors searched CENTRAL, the Cochrane Database of Systematic Reviews and MEDLINE and provided the full search strategies. It is likely that both reviews identified most potentially relevant studies [5] .
S T E P 4 : D I D T H E A U T H O R S I N C L U D E T H E R E L E VA N T S T U D I E S I N T H E R E V I E W ?
We now need to consider the process for identifying and including trials in the review. As we are asking a question about an intervention (whether statin treatment has specific effects), the most appropriate study design for inclusion is the randomized controlled trial. For the review to be reliable, there needs to be a robust transparent process for gathering all the relevant studies from the (often several thousand) citations obtained in the search. In other words, if a different team was tasked with the same research question and the same search results would they have found the same trials and included all of these in the systematic review? We need to know how the research team selected and included randomized trials identified by the search methods.
To ensure robust capture of relevant trials, two or more authors should consider each citation independently based on the PICO and discuss any discrepancies with each other or a third investigator. In the first review, two reviewers independently screened all citations by reading the title and abstract and then read the full article if necessary to identify relevant studies [4] . In the second review, five reviewers independently screened abstracts using a computer program although it was unclear whether all citations were read by more than one author and whether the full text of potentially relevant trials was reviewed before deciding on inclusion [5] .
S T E P 5 : D O A D D I T I O N A L R E S T R I C T I O N S O N T R I A L I N C L U S I O N C H A N G E T H E VA L I D I T Y A N D A P P L I CAT I O N O F T H E R E S U LT S ?
We also need to consider how restrictions placed on study entry might change the way we interpret the results. The first review included all trials regardless of the sample size and included those with follow-up longer than 8 weeks [4] . The second review restricted the number of participants in the trial to 100 or more in each treatment group and required a follow-up period of >6 months [5] .
The advantages of broader inclusion criteria in a systematic review are (i) larger sample size, (ii) potentially greater applicability of the results and (iii) greater capture of safety data. The first review included 80 trials involving 51 099 participants [4] , whereas the second review included 18 trials involving 36 529 participants [5] . A collectively larger sample size provides greater statistical power and may provide more precise results (if the included trials are sufficiently similar in important ways) ( Table 2) 
resources and funding. These trials could also be proof-of-concept studies. Therefore, inclusion of these studies may not provide enough data on clinical events such as death or cardiovascular events on their own but including these trials in meta-analyses potentially increases the ability of a meta-analysis to discern treatment effects on adverse events and discontinuation of study medications, which has been a major problem in nephrology trials [7, 8] .
S T E P 6 : I S T H E R E A M E TA -A N A LY S I S A N D W H AT D O T H E R E S U LT S M E A N ?
While a systematic review collates and summarizes qualitative evidence for a particular question, a meta-analysis combines the raw data from each study to summarize a quantitative estimate of treatment effects. A systematic review may or may not include a meta-analysis based on the type of research question and study design, the amount of available data and the consistency of the included studies (to be discussed below).
A meta-analysis is simply the pooling together of numerical data for a particular outcome. When the outcome is yes or no (a binary outcome such as being alive or dead at the end of treatment or being treated with dialysis or not), the estimated result is provided as a relative risk, rate ratio or odds ratio. When the outcome is a continuous variable (such as the blood pressure or eGFR at the study end), the summary estimate is commonly reported as the difference in the means between each treatment group (reported as the mean difference or standardized when the scales of measurement are different between studies). The summary effect in a meta-analysis is commonly reported with a 95% confidence interval (CI). In other words, we can be 95% certain that the true effect of treatment might lie between the upper and lower bounds of the 95% CI.
The results of a meta-analysis of randomized trials are often shown in a 'forest plot'. A hypothetical plot is shown in Figure 1 to explain how to interpret this for clinical practice. The key questions to consider when using a forest plot are (i) how many studies are there and how many participants are included? (ii) What is the overall treatment effect and how precise is this effect? (iii) Is the overall result statistically significant? (iv) How do the available studies contribute to the overall effect (which studies contribute the most and least data to the summary treatment effect)? (v) How similar are the available studies? See if you can answer these questions from the forest plot in Figure 1 .
How many studies and participants are there
In the forest plot, six studies have extractable data for major cardiovascular events from a hypothetical treatment or control in 6886 patients who have CKD. The number of events and the number of adults at risk in each treatment group of each study are provided along with the relative risk for each study. What is the overall treatment effect and how precise is this estimate: in the shaded blue area, the black filled in square for each study gives the point estimate of the relative risk. The line (or whisker) straddling the point estimate provides the 95% CI. The vertical line in the plot shows a relative risk of one (the risk of cardiovascular events is exactly the same in the treatment and control groups). When the 95% CI includes one (all studies in this example), then we have only a 5% chance that there is a true difference in the effect of treatment in the two different groups of participants (treatment and control). The combined treatment effect shown by a black diamond indicates an overall point estimate of 0.94 (the proportional reduction in major cardiovascular events is 6% for people receiving treatment), and we are 95% certain that the relative risk lies between 0.87 and 0.97 (between a 3 and 13% proportional reduction) as shown by the limits of the black diamond. It should be noted here that the overall treatment estimate from the meta-analysis is more precise than all of the included studies alone and shows the advantage of systematic review to discern a treatment benefit when individual studies lack sufficient power. Is the overall effect statistically significant: The summary treatment and its 95% CI are all <1 (to the right side of the vertical line), indicating that the treatment is likely to reduce cardiovascular events better than control. How do the available studies contribute to the overall effect? When we look at the weights [the amount of contribution the study gives to the overall result which in this case is related to the precision of its effects (inverse variance method)] shown in the right-hand column, data from Study C provides 74% of the information in the summary estimate and Studies D, E and F provide very little (<2%). Finally, we consider whether the studies give similar results. The plot shows that the 95% CIs for all studies overlap suggesting that the treatment effects on all six studies are statistically similar. When we measure this statistically, we find that the P-value for evidence of heterogeneity is 0.65 (meaning that the likelihood of important differences in treatment effects between different studies is low). This is confirmed by the I 2 value of 0%, meaning that the proportion of variation in treatment effects between studies that is beyond chance is probably 0% (it is possible to report a 95% CI for the I 2 square value, but this is rarely done). One can consider the I 2 thresholds of 0-40, 30-60, 50-90 and 75-100% to represent heterogeneity that is potentially unimportant, moderate, substantial or considerable, respectively [9] .
S T E P 7 : A R E T H E R E S U LT S F RO M D I F F E R E N T S T U D I E S S I M I L A R E N O U G H FO R T H E S U M M A RY T R E AT M E N T E F F E C T S TO B E M E A N I N G F U L ?
The analysis for the presence of heterogeneity in this hypothetical example suggests that the studies do not give results that vary beyond random chance (a heterogeneity P-value of >0.05 and an I 2 value of 0%) and are similar enough for the treatment estimates summarized by meta-analysis to be valid. If there is evidence of statistical heterogeneity within a metaanalysis (a heterogeneity P-value of <0.05 and an I 2 value of >30-40%), this suggests that the studies available do not provide similar results and a combined estimate may not be appropriate. Potential sources of heterogeneity include differences in study methods (bias) or differences in the study PICO ( population, intervention, comparator or outcome). When evidence of important heterogeneity is present, this might indicate that treatment has different effects for different patients and can give us clues as to which patients might benefit most (or least) from the intervention of interest.
When considering management decisions with Mrs DS, we can look at the summary treatment effects on major cardiovascular events in Review 1 to find that there is important heterogeneity in the meta-analysis for this outcome (P = 0.002 and I 2 value of 54%) [4] . Given that included trials conclude differing effects of statin treatment for patients treated with dialysis (some conclude benefit, whereas others do not), it was suspected that treatment might have different efficacy for dialysis patients compared with those with milder stages of kidney disease and that a meta-analysis combining data for these populations is unhelpful [1] [2] [3] . Subgroup analysis-where the meta-analysis is done separately for different groups of patients based on the existence of a variable that might contribute to heterogeneity-can help understand whether that variable is a source of heterogeneity in treatment effects between studies in the meta-analysis. In this, the analysis was done separately for groups of participants with differing stages of kidney disease (dialysis, CKD not requiring dialysis and transplant recipients). This indicated that while people with CKD Stages G1-G4 might experience marked proportional reductions in major cardiovascular events with statin therapy [RR 0.76 (95% CI 0.73-0.80)], adults treated with dialysis might expect to receive much smaller benefits from treatment (RR 0.95) and that we could not be certain that this reduction was statistically different from 1, or no effect (95% CI 0.87-1.03). Similarly in Review 2, there was evidence of statistical heterogeneity in the meta-analysis for allcause death with treatment benefits evident for people with kidney disease not treated with dialysis [RR 0.83 (95% CIs 0.70-0.98)] but smaller and uncertain benefits for people treated with dialysis [RR 0.96 (95% CI 0.90-1.02)] [5] . For Mrs DS, these results indicate that statin therapy might lower her risk of all-cause death by 17% [5] and her risk of a major cardiovascular event by 25% [4] but if she was treated with dialysis these benefits would be smaller and possibly absent.
S T E P 8 : H AV E T H E A U T H O R S A P P R A I S E D T H E R I S K S O F B I A S I N T H E I N C L U D E D T R I A L S ?
Not all trials are equally reliable. How trials are conducted and reported affects the validity and applicability of their results. An important role of a systematic review is not only to quantify treatment efficacy and safety, but also to consider and summarize the quality of the available evidence for clinical decisions. Risks of bias in randomized trials raise questions about whether a trial is likely to overestimate or underestimate the true intervention effect and may have an important influence on our confidence in the efficacy and safety of the treatments summarized by the review. Based on empirical data, bias in individual contributing studies should be adjudicated in terms of selection (was randomization likely to balance prognosis factors evenly between groups and were participants equally likely to get each of the planned interventions), performance (were there systematic differences in the care provided to each group other than the intervention under study?), detection (was the way in which outcomes were determined different in each treatment group?), attrition (were participants excluded from follow-up for reasons that might have related to the intervention?), reporting (were differences between intervention groups more likely to be reported than non-significant differences?) and other issues that are specific to particular study designs such as contamination of intervention effects after crossover of treatment [9] .
We can look to see whether the authors of the systematic review have considered and evaluated these risk domains and reported their considerations of the risks of bias in the evidence. In general, combining different risks of bias together (for example, combining all the bias domains) into a single score (for example, the Jadad score) might be simple and convenient but is not helpful for understanding the effects of the different sources of bias and requires subjective decisions to be made about the weighting of the differing contributions of each form of bias on our overall confidence in the results; the Cochrane Collaboration specifically advises against this approach. In the first systematic review, the risks of bias were assessed using the Cochrane Collaboration tool and the results for each domain were summarized in Figure 1 [4] . Overall, less than one-third of trials had a low risk of bias for most quality items, decreasing our confidence that the reported results are consistent with true treatment effects. In the second review, 'a predefined three-category grading system to denote the methodological quality of each study' was used and additional criteria were used to grade subgroup analyses in people with CKD who were available within trials of the general population, although this grading system combined multiple sources of bias [5] . In Review 2, the risks of bias were summarized for each outcome separately and detailed in Table 2 [5] . It appears that the key reason for downgrading confidence in the evidence related to the heavy reliance of the meta-analysis on CKD patient populations derived from trials conducted in larger populations. The impact of other sources of bias on the summary treatment estimates in this review was less clear.
S T E P 9 : H AV E T H E A U T H O R S R AT E D T H E Q U A L I T Y O F T H E E V I D E N C E ?
Grading the overall quality of the evidence is more than just assessing the risk of bias and is needed when interpreting the impact of the evidence on clinical practice. The evidence grade tells us how confident we might be in the results we see in the review and can be different for each specific clinical outcome. The grading process commonly uses the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology which takes into account (i) the risks of bias in the included studies, (ii) the precision of the resulting summary estimate of treatment effects, (iii) whether there is evidence of publication bias [are studies with specific results (either negative or positive) likely to be missing], (iv) whether the studies give consistent results and (v) whether the evidence can be generalized (for example, if the available trials were only conducted within a single specific setting such as diabetes, their application to a population without diabetes might be problematic) [10] . Randomized controlled trials start as high-quality evidence (★★★★), and the quality ranking may be reduced to moderate quality (★★★), low quality (★★) or very low quality (★) based on each of the GRADE components. For example, in the first review [4] , the evidence for the effects of statin treatment on major adverse cardiovascular events relevant to Mrs DS was graded as 'moderate quality' indicating we are 'confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different' [10] . Similarly, in the second review, while the GRADE methods were not used, 'the quality of evidence for cardiovascular events including the need for revascularization procedures was graded as moderate because of the inclusion of evidence from unplanned subgroup analyses of outcomes for patients with CKD enrolled in large RCTs [randomized controlled trials]' [5] . This similarly suggests that we can be confident in the treatment estimates from the meta-analysis.
S T E P 1 0 : A P P LY I N G T H E R E S U LT S O F T H E S Y S T E M AT I C R E V I E W TO T H E C L I N I CA L S C E N A R I O
Now we can use the data from the systematic reviews and metaanalyses to Mrs DS's questions about treatment. The ACC/ AHA Cardiovascular Risk Assessment Tool does not take into account the presence of CKD as an absolute risk factor for cardiovascular disease. Therefore, we need to interpret the estimated 10-year (4.3%) and lifetime (39%) risks for atherosclerotic cardiovascular disease for Mrs DS with caution. The ACC/AHA Cardiovascular Risk Assessment Tool provides 10-year risk estimates for individuals 40-79 years of age only. The Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Working Group recommend treatment with a statin or statin/ezetimibe combination in adults aged >50 years with eGFR <60 mL/min/1.73 m 2 but not treated with dialysis or kidney transplantation. This recommendation was based on the 10-year incidence risk of coronary death or non-fatal myocardial infarction >10% among CKD patients aged >50 years. The working group also found that the 10-year incidence risk of coronary death or non-fatal myocardial infarction was <10% among CKD patients aged <50 years. Therefore, we can indicate to Mrs DS that statin therapy is likely to provide her with a proportional reduction in major cardiovascular events of ∼25% and that we can be confident that this is a true estimate of her treatment benefit, although due to some limitations in the available studies there is a possibility that the treatment effect is substantially different. The absolute benefit of treatment is based on her baseline risk of cardiovascular disease, which has been estimated in previous cohort studies to ∼2% per year. In Review 1, statin therapy in CKD is estimated to prevent 5 patients in 1000 experiencing a cardiovascular event each year (95% CI 4-6 events) [4] . Mrs DS might now wish to consider whether this absolute effect of treatment is meaningful to her. In addition, she needs to know the potential adverse effects of treatment. While data for treatment hazards are low quality (we have low confidence in the results of the meta-analysis), there appears to be no important risks of side effects for Mrs DS. Mrs DS may now wish to balance our relative uncertainty of treatment hazards with the absolute benefits expected from treatment to consider whether she will take statin therapy. Based on the PICO of the studies included in Review 1, we can let her know that the evidence is based on statin therapy equivalent to simvastatin 20 mg daily and that no previous randomized trial has evaluated the effects of targeting a specific serum cholesterol level on treatment efficacy in adults who have CKD. Once she approaches end-stage kidney disease (eGFR <15 mL/min/1.73 m 2 ), the data on the benefits of statins become more uncertain. While patients who are treated with dialysis experience much smaller clinical benefits from statin therapy, the evidence for recipients of a kidney transplant is less certain and data for patients who commence dialysis while already treated with a statin are absent [4] . Once Mrs DS experiences kidney replacement therapy, she may then reasonably consider either continuing or discontinuing statin therapy based on her preferences regarding risks and benefits.
